

Meet AZN management: ASCO 2019 Breakout 4: trastuzumab deruxtecan

José Baselga, Executive Vice President, Oncology R&D




3 June 2019

Forward-looking statements

2

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and AstraZeneca undertakes no obligation to update these forward-looking statements. We identify the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things: the loss or expiration of, or limitations to, patents, marketing exclusivity or trademarks, or the risk of failure to obtain and enforce patent protection; effects of patent litigation in respect of IP rights; the impact of any delays in the manufacturing, distribution and sale of any of our products; the impact of any failure by third parties to supply materials or services; the risk of failure of outsourcing; the risks associated with manufacturing biologics; the risk that R&D will not yield new products that achieve commercial success; the risk of delay to new product launches; the risk that new products do not perform as we expect; the risk that strategic alliances and acquisitions, including licensing and collaborations, will be unsuccessful; the risks from pressures resulting from generic competition; the impact of competition, price controls and price reductions; the risks associated with developing our business in emerging markets; the risk of illegal trade in our products; the difficulties of obtaining and maintaining regulatory approvals for products; the risk that regulatory approval processes for biosimilars could have an adverse effect on future commercial prospects; the risk of failure to successfully implement planned cost reduction measures through productivity initiatives and restructuring programmes; the risk of failure of critical processes affecting business continuity; economic, regulatory and political pressures to limit or reduce the cost of our products; failure to achieve strategic priorities or to meet targets or expectations; the risk of substantial adverse litigation/government investigation claims and insufficient insurance coverage; the risk of substantial product liability claims; the risk of failure to adhere to applicable laws, rules and regulations; the risk of failure to adhere to applicable laws, rules and regulations relating to anti-competitive behaviour; the impact of increasing implementation and enforcement of more stringent anti-bribery and anti-corruption legislation; taxation risks; exchange rate fluctuations; the risk of an adverse impact of a sustained economic downturn; political and socio-economic conditions; the risk of environmental liabilities; the risk of occupational health and safety liabilities; the risk associated with pensions liabilities; the impact of failing to attract and retain key personnel and to successfully engage with our employees; the risk of misuse of social medial platforms and new technology; and the risk of failure of information technology and cybercrime. Nothing in this presentation / webcast should be construed as a profit forecast.

Trastuzumab deruxtecan A state-of-the-art HER2¹-targeted, second-generation ADC²



Potential best-in-class ADC for HER2-positive breast cancer

1. Human epidermal growth factor receptor 2.

2. Antibody drug conjugate.

3

Sources: Daiichi Sankyo R&D event, December 2018, US label for trastuzumab emtansine and Ogitani et al, 2016.


Differentiated ADC

- Higher-intensity chemotherapy (more payload on each antibody)
- Membrane permeability (potential HER2-low applicability)
- Selective protease-cleavable linker
- Short half-life of free payload reduces systemic toxicities

Potential first-in-class ADC for HER2-low cancers



Trastuzumab deruxtecan **Unprecedented Phase I/II data**



Progression-free survival in HER2-positive breast cancer

Source: Phase I, Tamura et al., The Lancet Oncology, 2019.

Differentiated ADC

59.5%

confirmed objective response rate

93.7%

confirmed disease control rate¹

20.7 months

median duration of response²

Unprecedented data in advanced **HER2-posistive breast cancer**

1. Disease control was calculated as the proportion of patients demonstrating complete response, partial response, or stable disease for a minimum of five weeks from the first dosing date 2. Not estimable.

Phase II primary endpoint met

News Release

AstraZeneca

Regulatory News Service

8 May 2019 07:00 BST

Trastuzumab deruxtecan demonstrated clinically-meaningful response in patients with refractory HER2-positive metastatic breast cancer, a population with high unmet need

> Pivotal Phase II DESTINY-Breast01 trial met primary endpoint. supporting global regulatory submission plan to start in H2 2019

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201). The HER2-targeting antibody drug conjugate (ADC) and potential new medicine was evaluated in patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine.

The response rate in DESTINY-Breast01, as assessed by an independent review committee, confirms in a heavily-pretreated, global patient population the unprecedented clinical activity in the recently-published Phase I trial. The safety and tolerability profile of trastuzumab deruxtecan was also consistent with previous experience. These results are expected to support planned global regulatory submissions, including a Biologics License Application with the US Food and Drug Administration (FDA) anticipated in the second half of 2019.

DESTINY-Breast01 is a pivotal Phase II, open-label, global, multicentre, two-part trial of trastuzumab deruxtecan. The optimal dose of 5.4mg/kg was previously identified in part one of the trial. Today's results from part two evaluated the efficacy and safety of that dose in patients who have failed or discontinued previous treatment with trastuzumab emtansine.

Phase II trial met primary endpoint in HER2+ breast cancer




Trastuzumab deruxtecan in breast cancer and beyond Opportunities across treatment settings in breast cancer

	Neo-adjuvant / adjuvant	1st-line metastatic	2nd-line metastatic	3rd-line metastatic
HER2-positive breast cancer	Post neo-adjuvant Replace trastuzumab emtansine chemotherapy + trastuzumab + pertuzumab	Replace chemotherapy + trastuzumab + pertuzumab	Replace trastuzumab emtansine	Post trastuzumab emtansine
HER2-low breast cancer	HR+ ¹ : chemotherapy ± endocrine therapy	endocrine ± CDK4/6i ²	Post CDK4/6i	
	TNBC ³ : chemotherapy	Replace 1st-line chemotherapy		
Beyond breast cancer	Expand into other cancer types: gastric, NSCLC ⁴ , CRC ⁵ and others			


1.Hormone-receptor positive 2. Cyclin-dependent kinase 4/6 inhibitor 3. Triple-negative breast cancer 4. Non-small cell lung cancer 5. Colorectal cancer.

Trastuzumab deruxtecan Encouraging efficacy in HER2-low breast cancer



HR: hormone receptor. IHC: immunohistochemistry. Source: poster # p6-17-02, SABCS 2018 (based on 12 October 2018 data cut off).

6




9.4 months DoR², 7.6 months median PFS³


Duration of response.
Progression-free survival.



Trastuzumab deruxtecan Compelling efficacy in other cancer types



Source: Phase I, Shitara et al., The Lancet Oncology.




73% ORR¹ 14.1 months median PFS¹

Source: abstract #13325, Tsurutani et al, WCLC 2018. 1. HER2-mutated NSCLC only.



Trastuzumab deruxtecan Development plans and news flow



Source: AstraZeneca data on file.

S

2. Breakthrough Therapy Designation.





Use of AstraZeneca conference call, webcast and presentation slides

The AstraZeneca webcast, conference call and presentation slides (together the 'AstraZeneca Materials') are for your personal, noncommercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the AstraZeneca Materials in any way. You may not edit, alter, adapt or add to the AstraZeneca Materials in any way, nor combine the AstraZeneca Materials with any other material. You may not download or use the AstraZeneca Materials for the purpose of promoting, advertising, endorsing or implying any connection between you (or any third party) and us, our agents or employees, or any contributors to the AstraZeneca Materials. You may not use the AstraZeneca Materials in any way that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. Telephone + 44 20 3749 5000, www.astrazeneca.com